

THE POSSIBLE ROLE OF DIDOQUIN AS A ZINC IONOPHORE
IN THE TREATMENT OF ACRODERMATITIS ENTEROPATHICA

P.J.Aggett, H.T.Delves, J.T.Harries

The Institute of Child Health
30 Guilford Street
London, WC1N 1EH

and

A. D. Bangham

The Institute of Animal Physiology,
Babraham, Cambridge

Received January 30, 1979

SUMMARY The mechanism by which 5,7-di-iodo-8-hydroxy quinoline (Didoquin) enhances zinc absorption in the zinc deficiency disorder acrodermatitis enteropathica was investigated using liposomes. This compound increased the permeability of the pure lipid membranes to ^{65}Zn and it is proposed that the therapeutic effect of Didoquin and related compounds may derive from their ability to act as ionophores.

INTRODUCTION Acrodermatitis enteropathica (AE), a rare autosomal recessive condition characterised by severe dermatitis, alopecia, diarrhoea and growth failure, is now known to be due to zinc deficiency (1). It was frequently fatal in childhood until it was fortuitously discovered that the antifungal agent 5,7-di-iodo-8-hydroxyquinoline (Didoquin) could induce a complete clinical remission (2). Subsequently the successful but empirical use of this and other halogenated derivatives of 8-hydroxyquinoline such as 5-chloro 7-iodo-8-hydroxyquinoline (Enterovioform) (3) and 2-methyl,5,7-dichloro-8-hydroxyquinoline (Sterosan) (4) and 5,7-dibromo-8-hydroxyquinoline (5) in this condition has been reported.

Abbreviations: AE Acrodermatitis enteropathica
TRIS Tris(hydroxymethyl)methylamine

0006-291X/79/060513-05\$01.00/0

The pathophysiological importance of zinc was first appreciated when Diodoquin was found to be ineffective in a child receiving a zinc deficient synthetic diet. It has since been shown that in the untreated patient with AE, the intestine is in a net secretory state with respect to zinc and that this is reversed to net absorption either by oral Diodoquin or zinc therapy alone (6). The latter has now superseded other treatments but the pharmacological mechanism for the action of Diodoquin in AE has not been investigated.

The known chelating properties of the di-halo-8-hydroxyquinolines have been invoked to propose two possible bases for their enhancement of zinc absorption, either they chelate an abnormal intestinal polypeptide which would otherwise bind zinc intraluminally and prevent its absorption (1) or they complex zinc itself forming a neutral complex which facilitates the mucosal uptake and absorption of zinc (7,8). The demonstration of an in vitro impairment of zinc uptake by small intestine mucosal biopsies from patients with AE (6) makes the latter hypothesis more tenable and we have investigated this using liposomes as model membranes.

MATERIALS AND METHODS

Liposomes comprising egg yolk phosphatidyl choline, phosphatidic acid and cholesterol in the molar ratios of 61, 5 and 33 with or without Diodoquin were prepared, as detailed elsewhere (9), by pipetting appropriate aliquots of stock chloroform solution into a glass tube. These were dried under vacuum and then totally resuspended in a solution of NaCl (94 mM) and Tris-chloride (5 mM) buffered at pH 7.5 containing ^{65}Zn labelled ZnCl_2 (80 μM). After equilibration under N_2 excess radiotracer was removed by passage of the lipid suspension through a Sephadex G50 medium grade column (Pharmacia). 2ml aliquots of lipid eluate was placed into dialysis bags (Visking 8/32) and these were transferred to stoppered glass tubes containing an identical but non-radiolabelled solution. The tubes were kept at 30°C in a constant temperature water bath and shaken throughout the

experiment. Samples of dialysate were taken at known intervals and their radioisotope content counted. The percentage of initial count remaining trapped within the liposomes was calculated.

The effect of pH on the complexation of zinc by Diodoquin was studied by measuring its extraction from a citrate buffered aqueous zinc chloride solution (50 $\mu\text{mol/l}$ of known pH into an equal volume of a solution of Diodoquin in chloroform (2 mmol/l). After mixing the two phases for two minutes the zinc content of the aqueous phase was determined by atomic absorption spectroscopy (Perkin Elmer 306) and the percentage extracted was calculated by comparison with control systems containing no Diodoquin.

All chemicals were of the purest grade supplied by British Drug Houses. $^{65}\text{ZnCl}_2$ was obtained from the Radiochemical Centre, Amersham, UK and the Diodoquin was a gift from May & Baker UK Ltd. The preparation of phosphatidyl choline and phosphatidic acid is described elsewhere (10).

RESULTS AND DISCUSSION

Diodoquin was found to increase the permeability of these pure lipid membranes to ^{65}Zn in a dose dependent manner (Fig.1). The incorporation of 1 μmol 8-hydroxyquinoline per 100 μmol s of lipid within the membrane induced a similar permeability to that caused by the same amount of Diodoquin. The relative impermeability to sucrose in the presence of Diodoquin (Fig. 2) excludes a significant non-specific effect on the membrane.

In the partition study Diodoquin was found to extract 90% of zinc from a 50 μM zinc chloride aqueous solution at pH 7.4 into a chloroform phase. The pH for 50% extraction was 6.5.

Our results support the hypothesis that Diodoquin enhances zinc absorption in AE by forming lipid-soluble complexes which enable the cation to traverse lipid bilayers. In this way it behaves as a pH dependent ionophore (11). The similar activity of 8-hydroxy-quinoline in this study and the therapeutic efficacy of




Figure 1 The effect of incorporating 0.5 ○, 1.0▲ and 5.0■ μmol of Diodoquin per 100 μmol of total lipid on the permeability of liposomes to ⁶⁵ZnCl₂ compared with controls containing no Diodoquin●

Figure 2 The percentage of radiolabel remaining in liposomes containing Diodoquin (1 μmol/100 μmol lipid), suspended in ¹⁴C labelled sucrose○ (1 mM) and ⁶⁵Zn labelled ZnCl₂▲ (80 μmol) compared with control preparations containing no Diodoquin●▲

its other 5,7-dihalo derivatives in AE suggests that the halogen moiety is unimportant but these do influence aqueous solubility and the pH characteristics of metal complexation (12), both of which may be important in therapeutic use.

ACKNOWLEDGEMENTS

PJA thanks the Medical Research Council for financial support.

REFERENCES

1. Moynahan, E.J. (1974) *Lancet* ii, 399-400.
2. Dillaha, C.J., Loricz, A.L., Aavik, O.R. (1953) *J.Amer.med.Ass.* 152, 509-512.
3. Papuzinski, M. (1960) *Przegl.derm.* 47, 207-213.
4. Danbolt, N. (1964) *Hautarzt* 15, 25-29.
5. Braun, O.H., Heilmann, K., Pauli, W. (1976) *Europ.J.Pediat.* 121, 247-261.
6. Aggett, P.J., Atherton, D., Thorn, J., Delves, H.T., Clayton, B.E., Harries, J.T., Bangham, A.D. (1978) *Trace Element Metabolism in Man and Animals* - 3. 418-422. (M.Kirchgesner, Ed), Institut fur Ernahrungsphysiologie, Technische Universitat Munchen, Freisin, Weihenstephan.
7. Delves, H.T., Harries, J.T., Lawson, M.S., Mitchell, J.D. (1975) *Lancet* ii, 929.
8. Portnoy, B., Molokhia, M. (1974) *Brit.J.Derm.* 91, 701-703.
9. Papahadjopoulos, D. and Watkins, J.C. (1967) *Biochim Biophys Acta*, 135, 639-652.
10. Bangham, A.D., Hill, M.E., Miller, N.G.A. (1974) *Preparation and use of liposomes as models of biological membranes.* In: *Methods in Membrane Biology* (Korn, E. Ed), Vol.I, Plenum Press, New York.
11. Pressman, B. (1976) *Ann.Rev.Biochem.* 45, 501-530.
12. Stary, J. (1964) *The Solvent Extraction of Metal Chelates.* Pergamon Press, London.